| Autor: |
Nieto-Ríos JF; Hospital Pablo Tobon Uribe, Colombia., Zuluaga-Quintero M; Universidad Pontificia Bolivariana, Colombia., Higuita LM; Universidad de Antioquia, Colombia., Rincón CI; Hospital Pablo Tobon Uribe, Colombia., Galvez-Cárdenas KM; Hospital Pablo Tobon Uribe, Colombia., Ocampo-Kohn C; Hospital Pablo Tobon Uribe, Colombia., Aristizabal-Alzate A; Hospital Pablo Tobon Uribe, Colombia., Florez-Vargas AA; Fundación Santa Fé de Bogotá, Colombia., Zuluaga-Valencia GA; Hospital Pablo Tobon Uribe, Colombia. |
| Jazyk: |
English; Portuguese |
| Zdroj: |
Jornal brasileiro de nefrologia [J Bras Nefrol] 2016 Jun; Vol. 38 (2), pp. 255-9. |
| DOI: |
10.5935/0101-2800.20160035 |
| Abstrakt: |
Gemcitabine is a medication used to treat various types of malignant neoplasms. Its association with hemolytic uremic syndrome (HUS) has been described in few cases, although these cases have resulted in mortality rates of at least 50%. We report on the case of a 25-year-old patient with cholangiocarcinoma in remission who developed microangiopathic hemolytic anemia with acute anuric renal failure after receiving 5 cycles of gemcitabine chemotherapy; this condition was consistent with HUS caused by the side effects of this drug. The administration of gemcitabine was stopped, and hemodialysis, blood transfusions, plasma exchanges, steroids, doxycycline, and rituximab were used to treat the patient. A favorable outcome was achieved; in particular, hemolysis was controlled, and renal function was completely recovered. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
